$5.28
1.03% today
Nasdaq, Sep 25, 05:18 pm CET
ISIN
US56400P7069
Symbol
MNKD

MannKind Corporation Stock price

$5.33
+1.43 36.67% 1M
+0.10 1.91% 6M
-1.10 17.11% YTD
-1.16 17.87% 1Y
+2.33 77.67% 3Y
+3.50 191.26% 5Y
-11.97 69.19% 10Y
-54.47 91.09% 20Y
Nasdaq, Closing price Wed, Sep 24 2025
-0.02 0.37%
ISIN
US56400P7069
Symbol
MNKD
Industry

Key metrics

Basic
Market capitalization
$1.6b
Enterprise Value
$1.7b
Net debt
$111.4m
Cash
$179.0m
Shares outstanding
306.3m
Valuation (TTM | estimate)
P/E
48.5 | 49.4
P/S
5.4 | 4.9
EV/Sales
5.8 | 5.3
EV/FCF
60.7
P/B
negative
Financial Health
Equity Ratio
-20.0%
Return on Equity
-35.0%
ROCE
26.6%
ROIC
36.7%
Debt/Equity
-5.3
Financials (TTM | estimate)
Revenue
$301.7m | $332.2m
EBITDA
$88.1m | -
EBIT
$79.7m | $56.8m
Net Income
$32.3m | $33.0m
Free Cash Flow
$28.8m
Growth (TTM | estimate)
Revenue
21.5% | 16.4%
EBITDA
72.5% | -
EBIT
74.6% | -21.7%
Net Income
175.8% | 19.7%
Free Cash Flow
57.8%
Margin (TTM | estimate)
Gross
77.4%
EBITDA
29.2% | -
EBIT
26.4%
Net
10.7% | 9.9%
Free Cash Flow
9.5%
More
EPS
$0.1
FCF per Share
$0.1
Short interest
5.3%
Employees
405
Rev per Employee
$700.0k
Show more

Is MannKind Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

MannKind Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a MannKind Corporation forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a MannKind Corporation forecast:

Buy
92%
Hold
8%

Financial data from MannKind Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
302 302
21% 21%
100%
- Direct Costs 68 68
3% 3%
23%
233 233
31% 31%
77%
- Selling and Administrative Expenses 105 105
15% 15%
35%
- Research and Development Expense 49 49
19% 19%
16%
88 88
72% 72%
29%
- Depreciation and Amortization 8.47 8.47
55% 55%
3%
EBIT (Operating Income) EBIT 80 80
75% 75%
26%
Net Profit 32 32
176% 176%
11%

In millions USD.

Don't miss a Thing! We will send you all news about MannKind Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MannKind Corporation Stock News

Neutral
Business Wire
9 days ago
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of scPharmaceuticals Inc. (NasdaqGS: SCPH) to MannKind Corporation (NasdaqGM: MNKD). Under the terms of the proposed transaction, shareholders of scPharmaceuticals would receive a cash payment of $5.3...
Neutral
Seeking Alpha
15 days ago
MannKind Corporation (NASDAQ:MNKD ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 2:35 PM EDT Company Participants Michael Castagna - CEO & Director Conference Call Participants Ross Cohen - Morgan Stanley Presentation Ross Cohen Great. Thank you all for joining us today, and welcome to the Morgan Stanley Healthcare Conference.
Neutral
Seeking Alpha
18 days ago
MannKind Corporation (NASDAQ:MNKD ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 4:30 PM EDT Company Participants Michael Castagna - CEO & Director Conference Call Participants Tiago Fauth - Wells Fargo Securities, LLC, Research Division Thomas Smith - Leerink Partners LLC, Research Division Presentation Tiago Fauth Equity Analyst All right. Perfect. Thanks, everyone, fo...
More MannKind Corporation News

Company Profile

MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.

Head office United States
CEO Michael Castagna
Employees 405
Founded 1991
Website mannkindcorp.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today